Vural, E.H.Gümüşel, B.2025-04-162025-04-1620251300-418210.55262/fabadeczacilik.15839432-s2.0-105001588001https://doi.org/10.55262/fabadeczacilik.1583943https://hdl.handle.net/20.500.14517/7817The financial and emotional burden of chronic diseases, including hypertension, has been rising. The objective of this study was to assess the trends in box sales of antihypertensive medications in Türkiye and to compare these trends across the antihypertensive medicine subgroups. This study analyzed retail and hospital box sales of antihypertensive drug groups recommended by guidelines between January 2019 and June 2024. The data used in this study were obtained from IQVIA. While antihypertensive drugs sold a total of 176,453,254 boxes in 2019, they were sold 203,690,099 boxes in 2023, a 15.44% increase. The best-selling drug group is the Renin-Angiotensin System (RAS) antagonists. Angiotensin Receptor Blocker-Diuretic fixed-dose combination (FDC) is the best-selling subgroup in the RAS antagonists. FDCs of RAS antagonists are more often used than their mono forms, and in 2022 and 2023, FDCs of calcium channel blockers have begun to outsell their combined formulations. Triple FDCs of the RAS antagonists with calcium channel blockers and diuretics have been increasing regularly. In Türkiye, drug groups that have had the highest share in the antihypertensive drug market in recent years are the groups recommended in the guidelines. Increasing the triple FDC consumption is valuable for the rational treatment of hypertension. © 2025 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.eninfo:eu-repo/semantics/closedAccessAntihypertensive DrugsBox SalesFixed-Dose CombinationRational Drug UseArticleN/AQ45016578